Arcturus Therapeutics has agreed to acquire Belgian AI drug-discovery company myNEO, expanding its computational capabilities for mRNA medicine design and target identification.

Boehringer Ingelheim and Envisagenics have entered a multi-year oncology collaboration worth more than $1 billion to discover therapeutic targets created by alternative RNA splicing.

AbbVie and Iambic have entered a multi-year collaboration to use artificial intelligence and computational drug discovery across immunology, neuroscience and oncology.

Novo Nordisk and Orbis Medicines have entered a multi-target drug-discovery partnership worth up to $1.4 billion to develop orally bioavailable macrocycle medicines for cardiometabolic disease.

A UK national commission has proposed a new regulatory framework for artificial intelligence in healthcare designed to support faster adoption while maintaining safety, accountability and public trust.

The acquisition combines Cureety's therapy-specific oncology monitoring platform with Reimagine Care's AI-enabled virtual cancer-care capabilities.

Qualcomm and ASUS have launched an on-premises AI assistant programme for community pharmacies across southern Taiwan.

The non-exclusive agreement gives SignalChem access to Monod Bio’s LuxSit luciferase and NovoBodies technologies for custom research assays and protein-fusion services, extending the commercial reach of its AI-designed protein platform.

The discussion paper launches a public consultation that could shape future regulatory expectations for AI-enabled medical devices, including premarket evaluation, risk assessment and postmarket monitoring.

The Canadian authorisation moves Light AI’s AI-enabled throat-image analysis platform from investigational development into its first regulated market, providing healthcare professionals with a software-based tool to support assessment of suspected Group A Streptococcus infection.

Pathos AI licenses first-in-class bispecific ADC JSKN016 from Alphamab Oncology in deal worth up to $4.8 billion

Healthcare organisations and technology developers face an expanding mix of state laws, sector-specific FDA expectations and federal policy initiatives rather than a single nationwide AI regulatory framework.

The latest agreement strengthens the companies’ collaboration as they target a major central nervous system indication using AI-powered drug discovery.

iPredict-DR uses artificial intelligence to analyse retinal images and support earlier detection of diabetic eye disease.

Zeta Surgical’s robotic navigation platform uses AI and computer vision to improve precision and repeatability during transcranial magnetic stimulation procedures.

The AI-powered software analyses retinal images captured by the widely used iCare DRSplus camera, supporting earlier detection of diabetic retinopathy in primary care and community healthcare settings.

The agreement will deploy Insilico’s Pharma AI platform across Takeda’s pipeline to accelerate early-stage drug discovery and candidate selection.

Boltz has entered a strategic partnership with Takeda to deploy its biomolecular AI models across the Japanese pharmaceutical company’s discovery organisation, strengthening its position in the rapidly expanding field of AI-enabled drug design.

The US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) have announced a new formal collaboration initiative

Merck & Co. has strengthened its commitment to AI-driven drug discovery through a new multi-year partnership with Protillion Biosciences, signing a deal worth up to $510 million focused on identifying and engineering novel therapeutic candidates.